Thursday, July 27, 2017 7:19:01 PM
Gene-based immunotherapy targeting a range of cancers
Status: Pre–Clinical complete
Immunotherapy
OXB-302 is a gene-based cancer immunotherapy targeting a wide range of tumours and a number of haematological malignancies.
Our approach
OXB-302 is a novel oncology product that combines Oxford BioMedica’s lentiviral vector platform and 5T4 technology platforms. This cell therapy uses the LentiVector® platform to engineer patients’ harvested T-cells to express an antibody against the 5T4 antigen, which is expressed on the cell surface in many common cancers. These T-cells are then infused back into the patient, and subsequently recognise the 5T4 tumour antigen and initiate cell killing immune mechanisms.
Proof of concept
OXB-302 has completed pre-clinical development, delivering encouraging efficacy in an industry standard in vivo tumour challenge model.
Clinical status
Following the successful completion of preclinical development, planning for a Phase I/II clinical study is well underway, with a regulatory submission anticipated in the near future.
Market opportunity
The targeted cancer treatment and immunotherapy market is forecast to grow to $36.8 billion by 2019. With a large number of cancers expressing the 5T4 antigen, OXB-302 has significant market potential if successful in any of its target indications.
http://www.oxfordbiomedica.co.uk/pipeline
Good luck and GOD bless,
George
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM